Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Earnings for Aura Biosciences, Inc. (AURA)
Earnings in 2023 (TTM): $-76,271,000
According to Aura Biosciences, Inc.'s latest financial reports the company's current earnings (TTM) are $-76,271,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Aura Biosciences, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-76,271,000 | $-76,408,000 |
| 2022 | $-58,763,000 | $-57,231,000 |
| 2021 | $-35,251,000 | $-34,421,000 |
| 2020 | $-22,206,000 | $-22,209,000 |
| 2019 | $-24,200,000 | $-24,205,000 |